[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584477":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":24,"overallOfficials":13,"centralContacts":30,"locations":36,"responsibleParty":77,"collaborators":13,"id":79,"slug":13,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":13,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":13,"enrollmentInfo":87,"targetDuration":90,"studyType":91,"phases":13,"briefSummary":92,"conditions":93,"keywords":13,"overallStatus":39,"whyStopped":13,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"ADVANCED MARKER DISCOVERY S.L.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"False Positive Rate","To estimate the false positive rate of the blood-based test in the main population of the study","36 month",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","Patients will be enrolled with a only one diagnosis of cancer (no colorectal cancer) or gastrointestinal disease at the time of a consultation within the Oncology, Digestive System, Gastroenterology, Endoscopy or Surgery Service. Patients will be included in a competitive, consecutive and progressive manner by the Centers.",[19],{"label":20,"type":13,"description":21,"interventionNames":22},"Cancer or Gastrointestinal Disease","A different types of cancer and gastrointestinal disease will be included in the cohort such as breast cancer, bladder cancer, IBDs, Leukemia and Lung cancer.",[23],"Diagnostic Test: blood sampling",[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":13},"DIAGNOSTIC_TEST","blood sampling","Patients will donate a blood sample for molecular analysis of molecular biomarkers in plasma, which being the only procedure in the study.",[20],[31],{"name":32,"role":33,"phone":34,"phoneExt":13,"email":35},"Marta Jimenez","CONTACT","+34637899149","mjimenez@amadix.com",[37,50,54,63,71],{"facility":38,"status":39,"city":40,"state":41,"zip":13,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":13},"Hospitales HM de Malaga","RECRUITING","Málaga","Andalusia","Spain","ES",{"type":45,"coordinates":46},"Point",[47,48],-4.42034,36.72016,{"lat":48,"lon":47},{"facility":51,"status":39,"city":52,"state":53,"zip":13,"country":42,"countryCode":43,"cosmosGeoPoint":13,"geoPoint":13,"contacts":13},"Hospital Centro Médico Asturias","Oviedo","Cantabria",{"facility":55,"status":39,"city":56,"state":57,"zip":13,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":13},"Hospital Universitario de Ourense","Ourense","Galicia",{"type":45,"coordinates":59},[60,61],-7.86407,42.33669,{"lat":61,"lon":60},{"facility":64,"status":39,"city":65,"state":65,"zip":13,"country":42,"countryCode":43,"cosmosGeoPoint":66,"geoPoint":70,"contacts":13},"Hospital Universitario HM Sanchinarro","Madrid",{"type":45,"coordinates":67},[68,69],-3.70256,40.4165,{"lat":69,"lon":68},{"facility":72,"status":73,"city":65,"state":65,"zip":13,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":76,"contacts":13},"MD Anderson Cancer Centre","ACTIVE_NOT_RECRUITING",{"type":45,"coordinates":75},[68,69],{"lat":69,"lon":68},{"type":78,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100584477",false,"NCT06889844","Observational Cross-reactivity Study for Colorectal Cancer Diagnosis","Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools","Inclusion Criteria:\n\n* Patients older than 18 years of age at the time of blood sample collection.\n* Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form.\n* Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.\n\nExclusion Criteria:\n\n* Patients who have received previous chemotherapy or radiotherapy.\n* In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor.\n* Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome.\n* Patients without appropriate staging or diagnosis.\n* Patients with hemolyzed plasma.","ALL","18 Years",{"count":88,"type":89},250,"ESTIMATED","1 Day","OBSERVATIONAL","The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is\n\nDoes the blood test have a low false positive rate in the main study population?\n\nParticipants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.",[94],"Colorectal Cancer","2025-09-29",{"date":97,"type":98},"2025-10-01","ACTUAL",{"date":100,"type":98},"2023-04-17",{"date":102,"type":89},"2025-12",{"name":5,"class":6},5]